HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Ralph A. Schmid Walter Weder Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hillinger, S. Articles by Weder, W. Search for Related Content PubMed PubMed Citation Articles by Hillinger, S. Articles by Weder, W.

Eur J Cardiothorac Surg 1999;15:475-480
© 1999 Elsevier Science NL

Donor and recipient treatment with the Lazaroid U-74006F do not improve post-transplant lung function in swine¹

^a Department of Surgery, University Hospital, Zürich, Switzerland
^b Pulmonary Division, Department of Internal Medicine, University Hospital, Zürich, Switzerland
^c Department of Anesthesiology, University Hospital, Zürich, Switzerland

Received 22 June 1998; received in revised form 14 December 1998; accepted 12 January 1999.

Corresponding author. Tel.: +41 1 255 8804; fax: +41 1 255 8805.

Objective: U-74006F is the only Lazaroid which is currently in clinical use. A number of experimental studies demonstrate that Lazaroids reduce ischemia/reperfusion injury in various organ systems. We evaluated the effect of U-74006F on reperfusion injury in a large animal model of lung allo-transplantation. Methods: Two different treatment modalities were evaluated and compared with corresponding control groups. Unilateral left lung transplantation was performed in 21 weight-matched pigs (24–31 kg). Donor lungs were flushed with 1.5 l cold (1°C) LPD solution and preserved for 20 h. In group I (n=5), donor animals were pretreated with U-74006F (10 mg/kg i.v.) 20 min before harvest. In addition U-74006F was added to the flush solution (10 mg/l). In group III (n=6), the Lazaroid was given to the donor before flush and to the recipient before reperfusion (3 mg/kg i.v.). Group II and IV (n=5) served as control. One hour after reperfusion, the recipient contralateral right pulmonary artery and bronchus were ligated to assess graft function only. Extravascular lung water index (EVLWI), mean pulmonary artery pressure, cardiac output, and gas exchange were assessed during a 5 h observation period. Lipid peroxidation (TBARS) and neutrophil migration (MPO activity) were measured at the end of the assessment in lung allograft tissue. Results: A significant change of TBARS concentration was shown in group III (group III 78.7±4.6 pmol/g vs. group IV 120.8±7.2 pmol/g (P=0.0065) normal lung tissue 41.3±4.2 pmol/g). MPO activity was reduced in group III 3.74±0.25 OD/mg per min vs. group IV 4.97±0.26 OD/mg per min (P=0.027), normal lung tissue 1.04±0.27 OD/mg per min). Pulmonary hemodynamics and gas exchange after reperfusion did not differ between groups. In group I and III, a tendency towards a reduced EVLWI was noted. Conclusion: We conclude that combined treatment of donor and recipient with U-74006F reduces free radical mediated injury in the allograft. However, this intervention did not result in a significant reduction of post-transplant lung edema or improvement of pulmonary hemodynamics. Donor pretreatment alone did not improve lung allograft reperfusion injury. These results indicate that the benefit of U-74006F is too small to consider clinical application in lung transplantation.

Key Words: Lung transplantation • Reperfusion injury • Lazaroids • Animal model • Swine